Humacyte, Inc. announced on October 8, 2025 that it had entered into a securities purchase agreement with institutional investors to raise approximately $60.0 million through an oversubscribed registered direct offering of its common stock and warrants. The transaction will involve the sale of 28,436,018 shares of common stock and an equal number of warrants, each exercisable 180 days after issuance at an exercise price of $2.11 per share, with the warrants expiring on April 7, 2031.
The offering is being conducted under a shelf registration statement on Form S‑3 (File No. 333‑290231) that was declared effective by the SEC on September 22, 2025. D. Boral Capital LLC is acting as the exclusive placement agent, and the offering is expected to close on or about October 8, 2025, subject to customary closing conditions. The gross proceeds are estimated at $60.0 million before placement agent fees and other offering expenses.
This financing event provides Humacyte with additional capital to support its commercial launch of Symvess, expand its pipeline, and extend its cash runway into the second half of 2026, thereby strengthening the company’s financial position and enabling continued investment in its bioengineered tissue platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.